June 15 (Reuters) - Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ...
The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy ...
Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...
The U.S. Food and Drug Administration has approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC). The approval was based on results from the ELEVATE UC ...
Omvoh is a biologic medicine used to treat moderate to severe ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease that causes inflammation in parts of the digestive tract. Common ...
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results